When National Security Becomes a Deal Term: What the Korea Zinc Battle and Roche-PathAI Tell Us About 2026 M&A

In the first week of May 2026, two stories landed on opposite sides of the Pacific — and they told the same story.

In Seoul, The Korea Herald and The Investor reported that national security reviews are no longer a predictable procedural step in Korean cross-border M&A. They have become a strategic weapon. Lawmakers from both ruling and opposition parties are now pushing legislation that would extend security screening to minority stake acquisitions and indirect investments — not just controlling interests. The Korea Zinc vs. MBK battle in 2024 was the opening act: a domestic private equity firm with significant foreign investor exposure was subjected to national security arguments by the target company's management as a defense mechanism.

In Boston, Roche announced on May 7 that it has entered into a definitive merger agreement to acquire PathAI — an AI-powered digital pathology company — for $750 million upfront, with milestone payments of up to $300 million additional, for a potential total of $1.05 billion. The rationale was explicit: when AI algorithms become core clinical infrastructure, you cannot afford to license them from a third party indefinitely. You own them, or your competitor will.

The Common Logic

Both stories are expressions of the same underlying shift in M&A strategy: control of critical assets is now a first-order dealmaking criterion.

Research published in the Journal of World Investment & Trade (2021) analyzing FDI screening mechanisms across Germany and China found that unpredictability, procedural uncertainty, and lack of transparency are the three primary regulatory hurdles that deter foreign investment in jurisdictions with national security screening. Korea's emerging legislative framework risks replicating all three. As the study noted, screening regimes must balance national security imperatives with investor certainty — a balance South Korea has not yet codified in statute.

A 2023 UNCTAD research report documented that between 2020 and 2022, at least 12 jurisdictions introduced 25 new screening measures, with the majority aimed at restricting foreign investments or creating more elaborate review regimes. The trend has not slowed. If Korea extends screening to minority stakes and indirect investments — as current legislative proposals suggest — it will join a growing cohort of countries where a 10% stake acquisition in a semiconductor or battery company can trigger a full national security review.

Korea Parallel

The implications for Korean M&A dealmakers are direct. First, cross-border deals involving companies with designated national core technologies — particularly in semiconductors, batteries, and now AI diagnostics — must account for parallel regulatory review tracks from Day 1. National security review timelines are neither short nor predictable. Building contingency clauses and extended long-stop dates into SPAs is no longer optional.

Second, RaymondsIndex data shows that deals accompanied by governance disputes have a substantially lower integration success rate by d>0.8 standards — 78% baseline falling to 61% when conflict extends into the post-signing period. National security review delays create exactly this kind of extended uncertainty window, during which key personnel may exit, integration momentum stalls, and cultural alignment work cannot begin.

Third, the Roche-PathAI deal offers a structural template worth studying. Roche's phased acquisition — building a partnership from 2021, expanding it in 2024, then executing a full acquisition in 2026 — avoided the cold-start integration problem. Korean corporates pursuing AI capability acquisitions, particularly in healthcare and defense-adjacent industries, should consider the same "partnership-to-acquisition" pathway precisely because it reduces the informational asymmetry that national security screening often magnifies.

The PMI Implication

Post-merger integration practitioners need to update their playbooks. The regulatory risk layer — which previously meant antitrust approval — now includes national security screening timelines, stakeholder communication strategies for review delays, and scenario planning for conditional approvals that require asset divestiture.

In 2026, the deals that succeed will be the ones where the integration team was briefed on regulatory risk before the term sheet was signed — not after.

References:
1. "Foreign Direct Investment Screening and National Security: Reducing Regulatory Hurdles to Investors Through Induced Reciprocity." Journal of World Investment & Trade, Vol. 22, Issue 4 (2021). Brill. https://brill.com/view/journals/jwit/22/4/article-p561_3.xml
2. UNCTAD. "The evolution of FDI screening mechanisms: Key trends." UNCTAD Research Paper, 2023. https://unctad.org/system/files/official-document/diaepcbinf2023d2_en.pdf